A detailed history of Black Rock Inc. transactions in Viracta Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 273,297 shares of VIRX stock, worth $68,324. This represents 0.0% of its overall portfolio holdings.

Number of Shares
273,297
Previous 303,980 10.09%
Holding current value
$68,324
Previous $310,000 52.58%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$0.5 - $1.17 $15,341 - $35,899
-30,683 Reduced 10.09%
273,297 $147,000
Q1 2024

May 10, 2024

SELL
$0.48 - $1.13 $802 - $1,889
-1,672 Reduced 0.55%
303,980 $310,000
Q4 2023

Feb 13, 2024

SELL
$0.44 - $1.04 $367 - $869
-836 Reduced 0.27%
305,652 $174,000
Q3 2023

Nov 13, 2023

SELL
$1.03 - $1.58 $158,359 - $242,920
-153,747 Reduced 33.41%
306,488 $318,000
Q2 2023

Aug 11, 2023

BUY
$0.89 - $2.13 $11,066 - $26,484
12,434 Added 2.78%
460,235 $648,000
Q1 2023

May 12, 2023

SELL
$1.38 - $2.29 $378 - $627
-274 Reduced 0.06%
447,801 $712,000
Q4 2022

Feb 13, 2023

SELL
$1.26 - $4.38 $270,301 - $939,619
-214,525 Reduced 32.38%
448,075 $654,000
Q3 2022

Nov 14, 2022

BUY
$3.32 - $5.69 $398,961 - $683,761
120,169 Added 22.15%
662,600 $2.83 Million
Q2 2022

Aug 12, 2022

SELL
$1.87 - $5.0 $3.31 Million - $8.85 Million
-1,770,477 Reduced 76.55%
542,431 $2.1 Million
Q1 2022

May 12, 2022

SELL
$2.23 - $4.76 $124,902 - $266,607
-56,010 Reduced 2.36%
2,312,908 $11 Million
Q4 2021

Feb 10, 2022

BUY
$3.37 - $7.91 $956,641 - $2.25 Million
283,870 Added 13.61%
2,368,918 $8.65 Million
Q3 2021

Nov 09, 2021

BUY
$7.84 - $12.53 $187,195 - $299,178
23,877 Added 1.16%
2,085,048 $16.7 Million
Q2 2021

Aug 11, 2021

BUY
$7.55 - $12.95 $15.6 Million - $26.7 Million
2,061,171 New
2,061,171 $23.4 Million

Others Institutions Holding VIRX

About Viracta Therapeutics, Inc.


  • Ticker VIRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,558,200
  • Market Cap $9.39M
  • Description
  • Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...
More about VIRX
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.